Annemarie Armani

Summary

Publications

  1. ncbi Colesevelam hydrochloride in the management of dyslipidemia
    Annemarie Armani
    Imprint Science, 230 Park Avenue South New York, NY 10003, USA
    Expert Rev Cardiovasc Ther 4:283-91. 2006
  2. ncbi The biology, utilization, and attenuation of C-reactive protein in cardiovascular disease: part II
    Annemarie Armani
    IntraMed Scientific Solutions, New York, NY, USA
    Am Heart J 149:977-83. 2005
  3. ncbi The CARDS trial: diabetic patients dealt a winning hand
    Annemarie Armani
    Sterling Rock Falls Clinic, 101 East Miller Road, Sterling, IL 61081, USA
    Curr Atheroscler Rep 8:429-32. 2006
  4. ncbi Safety considerations with fibrate therapy
    Michael H Davidson
    Rush University Medical Center, Chicago, Illinois, USA
    Am J Cardiol 99:3C-18C. 2007
  5. ncbi Safety considerations with gastrointestinally active lipid-lowering drugs
    Terry A Jacobson
    Emory University, Office of Health Promotion and Disease Prevention, Atlanta, Georgia 30303, USA
    Am J Cardiol 99:47C-55C. 2007
  6. ncbi SPARCL: the glimmer of statins for stroke risk reduction
    Annemarie Armani
    Sterling Rock Falls Clinic, 101 East Miller Road, Sterling, IL 61081, USA
    Curr Atheroscler Rep 9:347-51. 2007

Detail Information

Publications6

  1. ncbi Colesevelam hydrochloride in the management of dyslipidemia
    Annemarie Armani
    Imprint Science, 230 Park Avenue South New York, NY 10003, USA
    Expert Rev Cardiovasc Ther 4:283-91. 2006
    ..Colesevelam has a favorable side effect and toxicity profile and significantly impacts serum levels of lipoproteins when used as monotherapy or when used in combination with either statins or ezetimibe...
  2. ncbi The biology, utilization, and attenuation of C-reactive protein in cardiovascular disease: part II
    Annemarie Armani
    IntraMed Scientific Solutions, New York, NY, USA
    Am Heart J 149:977-83. 2005
  3. ncbi The CARDS trial: diabetic patients dealt a winning hand
    Annemarie Armani
    Sterling Rock Falls Clinic, 101 East Miller Road, Sterling, IL 61081, USA
    Curr Atheroscler Rep 8:429-32. 2006
    ..Benefit emerged within 1 year of initiating therapy...
  4. ncbi Safety considerations with fibrate therapy
    Michael H Davidson
    Rush University Medical Center, Chicago, Illinois, USA
    Am J Cardiol 99:3C-18C. 2007
    ....
  5. ncbi Safety considerations with gastrointestinally active lipid-lowering drugs
    Terry A Jacobson
    Emory University, Office of Health Promotion and Disease Prevention, Atlanta, Georgia 30303, USA
    Am J Cardiol 99:47C-55C. 2007
    ..Overall, CAIs and BAS have excellent systemic safety profiles when used alone or in combination with other lipid-lowering drugs...
  6. ncbi SPARCL: the glimmer of statins for stroke risk reduction
    Annemarie Armani
    Sterling Rock Falls Clinic, 101 East Miller Road, Sterling, IL 61081, USA
    Curr Atheroscler Rep 9:347-51. 2007
    ..Patients with a history of stroke should be treated much more aggressively with statin therapy in order to more optimally reduce risk for stroke recurrence...